C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

By M. Mosli, G. Zou, Sushil Garg, Sean G Feagan, J. Macdonald, N. Chande, W. Sandborn, B. Feagan. American Journal of Gastroenterology, 2015

621 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/3362c4ed2e3c4916f8e16f04a4a527d0b2612d48

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Schneider
2. C. Lacchetti
3. J. Naidoo
4. L. Nastoupil
5. M. Atkins
6. B. Santomasso
7. Kelly J. Brassil
8. M. Ernstoff

Citations in the corpus

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “The elevation of fecal calprotectin has been shown in inflammatory bowel disease to be a proxy for mucosal damage, and its normalization is associated with mucosal healing.(76,77) It should be noted that for malignancies involving the GI tract, fecal calprotectin has been observed to be elevated bec”